In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on BioNTech SE, with a price target of $128.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evan Seigerman has given his Buy rating due to a combination of factors tied to BioNTech’s shifting focus and financial strength. He views the company’s transition from relying on COVID-19 vaccine revenues toward advancing its oncology portfolio as on track, supported by steady full-year COVID guidance, robust cash of €16.8B, and a $1B share repurchase that signals confidence and disciplined capital allocation.
Seigerman also highlights growing momentum in the oncology pipeline, with pumitamig positioned as a potentially scalable immuno-oncology backbone and gotistobart showing encouraging early efficacy and safety signals that could underpin future launches. Together with anticipated 2026 data catalysts, expected stability in the COVID franchise, and ample resources for business development, these elements support his view that the shares offer attractive upside at an unchanged $128 price target.
Seigerman covers the Healthcare sector, focusing on stocks such as Merck & Company, Novo Nordisk, and Eli Lilly & Co. According to TipRanks, Seigerman has an average return of 7.9% and a 50.40% success rate on recommended stocks.
In another report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $158.00 price target.